Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AGEN
CUSIP00847G70
Phone781-674-4400
Debt
Debt-to-Equity Ratio-0.11
Current Ratio2.16
Quick Ratio2.16
Price-To-Earnings
Trailing P/E Ratio-2.06
Forward P/E Ratio-1.61
P/E GrowthN/A
Sales & Book Value
Annual Sales$42.88 million
Price / Sales6.14
Cash FlowN/A
Price / CashN/A
Book Value($0.74) per share
Price / Book-3.42
Profitability
EPS (Most Recent Fiscal Year)($1.23)
Net Income$-120,690,000.00
Net Margins-281.49%
Return on EquityN/A
Return on Assets-98.89%
Miscellaneous
Employees255
Outstanding Shares104,000,000
Agenus (NASDAQ:AGEN) Frequently Asked Questions
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc (NASDAQ:AGEN) released its earnings results on Monday, May, 7th. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.14. View Agenus' Earnings History.
When is Agenus' next earnings date?
What price target have analysts set for AGEN?
1 brokers have issued 12-month price objectives for Agenus' shares. Their predictions range from $7.00 to $7.00. On average, they expect Agenus' share price to reach $7.00 in the next twelve months. View Analyst Ratings for Agenus.
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include BAVARIAN NORDIC/S (BVNRY), Solid Biosciences (SLDB), Coherus Biosciences (CHRS), La Jolla Pharmaceutical (LJPC), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Mesoblast (MESO), CASI Pharmaceuticals (CASI), Scholar Rock (SRRK), Nightstar Therapeutics (NITE), Vericel (VCEL) and Surface Oncology (SURF).
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 65)
- Ms. Christine M. Klaskin, VP of Fin. (Age 52)
- Dr. Alexander R. Duncan, CTO & Head of Research (Age 56)
- Ms. Karen Higgins Valentine, Chief Legal Officer & Gen. Counsel (Age 46)
- Dr. Robert B. Stein, Sr. R&D Advisor (Age 67)
Has Agenus been receiving favorable news coverage?
Media headlines about AGEN stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Agenus earned a coverage optimism score of 0.05 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.68 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Agenus' major shareholders?
Agenus' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.75%), Point72 Asset Management L.P. (3.34%), Artal Group S.A. (2.64%), Northern Trust Corp (0.93%), Millennium Management LLC (0.91%) and venBio Select Advisor LLC (0.68%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin, Corp Incyte, Garo H Armen, Karen Valentine and Ulf Wiinberg. View Institutional Ownership Trends for Agenus.
Which institutional investors are selling Agenus stock?
AGEN stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Millennium Management LLC, Candriam Luxembourg S.C.A. and Chicago Equity Partners LLC. Company insiders that have sold Agenus company stock in the last year include Alex Duncan, Christine M Klaskin and Karen Valentine. View Insider Buying and Selling for Agenus.
Which institutional investors are buying Agenus stock?
AGEN stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Artal Group S.A., UBS Group AG, BlackRock Inc., Russell Investments Group Ltd., Northern Trust Corp, Barclays PLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Agenus stock in the last two years include Corp Incyte, Garo H Armen and Ulf Wiinberg. View Insider Buying and Selling for Agenus.
How do I buy shares of Agenus?
Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of AGEN stock can currently be purchased for approximately $2.53.
How big of a company is Agenus?
Agenus has a market capitalization of $280.80 million and generates $42.88 million in revenue each year. The biotechnology company earns $-120,690,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Agenus employs 255 workers across the globe.
How can I contact Agenus?
Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]
MarketBeat Community Rating for Agenus (AGEN)
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
